Drug Profile
Monosodium alpha luminol - Bach Pharma
Alternative Names: Galavit; GVTLatest Information Update: 08 Jul 2019
Price :
$50
*
At a glance
- Originator The Center of Modern Medicine (Medicor)
- Developer Bach Pharma
- Class Antiallergics; Antineoplastics; Antiparkinsonians; Eye disorder therapies; Phthalazines; Radioprotectives; Small molecules; Sodium compounds
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Immunological disorders
- Registered Cancer; Female genital diseases; Inflammation
- Phase III Breast cancer; Small cell lung cancer
- Phase II Dry eyes; Hypersensitivity; Wounds
- No development reported Ataxia telangiectasia; Chronic obstructive pulmonary disease; Glaucoma; Metabolic syndrome; Neurological disorders; Parkinson's disease; Radiation injuries
Most Recent Events
- 08 Jul 2019 Chemical structure information added
- 16 Jul 2016 No recent reports of development identified for phase-I development in Ataxia-telangiectasia in USA (IM, Injection)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Ataxia-telangiectasia in USA (PO)